Table 1.

Patient characteristics (N=41)

Variable	Median (Range)
Age at diagnosis (years)	41.3 (21.0, 73.7)
	n (%)
Ethnicity
White	31 (75.6)
Black	4 (9.8)
Hispanic	3 (7.3)
Other	3 (7.3)
FIGO stage at initial diagnosis
I or II	3 (7.3)
III or IV	35 (85.4)
Unknown	3 (7.3)
Disease status at end of primary cytoreductive surgery
No gross residual	7 (17.0)
Gross residual	24 (58.5)
Unknown	10 (24.4)
Adjuvant therapy
Surveillance	4 (9.8)
Chemotherapy
Platinum + taxane	26 (63.4)
Platinum, single agent	5 (12.2)
Platinum + cyclophosphamide	3 (7.3)
Platinum + taxane + bevacizumab	1 (2.4)
Platinum + hormonal agent	1 (2.4)
Hormonal therapy
Letrozole	1 (2.4)
Maintenance therapy
Chemotherapy
Platinum	2 (4.9)
Hormonal therapy
Letrozole	4 (9.8)
Tamoxifen	5 (12.2)
Leuprolide acetate	1 (2.4)